We took a systematic approach, using RNA-seq, exome-seq, and SNP array to identify genetic and non-genetic alterations that emerge following long-term exposure of the PTEN-deficient prostate cancer cell line, LNCaP, to allosteric or ATP-competitive AKT inhibitors. The gene discussed is PTEN; the disease is prostate cancer.